Introducing Insudex®

The first and only point-of-care tests for early detection of type-1 diabetes and LADA
(Latent Autoimmune Diabetes in Adults)

Salient Features of Insudex® Test

10-15 minutes to read from a finger stick or serum sample

Quantitative autoantibody titers obtained with reader

Who Should Use Insudex®?

Children with suspected classical Type 1 diabetes and their siblings.

Children or adolescents who present with putative Type 2 diabetes, but who may, in fact, have Type 1 diabetes.

Adults suspected of having Type 1 diabetes.

Patients with established or pre (Type 2) diabetes.

Diabetes patients who may have developing or established autoimmune complications.

Pregnant women with putative gestational diabetes who may have undiagnosed Type 1 diabetes.


Autoantibodies can be present years before clinical symptoms:
a tool for early prediction of risk.

Introducing the first and only point-of-care tests for early detection of type-1 diabetes and LADA

(Latent Autoimmune Diabetes in Adults)


Three Tests for Three Autoantibodies:

Insulin Autoantibodies to insulin (IAA) can predict risk of type-1 diabetes or confirm a diagnosis of type-1 diabetes. IAA are most common in children with or at risk for type-1 diabetes.

GAD, GAD65 Autoantibodies to GAD (GADA), like IAA, are also predictive of risk for type-1 diabetes. GAD autoantibodies are present in the majority of adult patients with autoimmune diabetes.

IA-2 Autoantibodies against IA-2 (IA2-A) are the second most common autoantibody in type-1 diabetes. GAD and IA-2 autoantibodies are the most common in type-2 diabetes that also has an autoimmune component.

For children, the number of autoantibodies present is a better predictor of disease risk than the presence of any single antibody.


Who Should Be Tested

 Children with suspected classical type-1 diabetes and their siblings.

 Children or adolescents who present with putative type-2 diabetes, but who may, in fact, have type-1 diabetes. These patients are a distinct group that is not distinguishable without autoantibody screening, and may benefit from different interventions.

 Adults suspected of having type-1 diabetes, since a significant proportion of type-1 diabetes patients are diagnosed as adults.

 Patients with established or pre (type-2) diabetes in which the presence of autoantibodies in addition to insulin resistance may predict a more rapid progression to insulin deficiency.

 Diabetes patients who may have developing or established autoimmune complications such as celiac disease or autoimmune thyroid disease.

 Pregnant women with putative gestational diabetes who may have undiagnosed type-1 diabetes.


About the Reader

Our reader is a first-of-its-kind, quantitative, reader that incorporates real-time test data acquisition and transfer to mobile devices.

Pending FDA approval
Scroll to top

Choose site:

Diabetomics India (diabetomics.in)

Diabetomics, Inc. USA (diabetomics.com)

In response to COVID-19 pandemic, Diabetomics is leveraging its oral fluid rapid test technology to develop a home use SARS-CoV-2 antibody test.

covabscreen.com
X myStickymenu